학술논문
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
Document Type
Article
Author
Cameron, David; Morden, James P; Canney, Peter; Velikova, Galina; Coleman, Robert; Bartlett, John; Agrawal, Rajiv; Banerji, Jane; Bertelli, Gianfilippo; Bloomfield, David; Brunt, A Murray; Earl, Helena; Ellis, Paul; Gaunt, Claire; Gillman, Alexa; Hearfield, Nicholas; Laing, Robert; Murray, Nicholas; Couper, Niki; Stein, Robert C; Verrill, Mark; Wardley, Andrew; Barrett-Lee, Peter; Bliss, Judith M
Source
In The Lancet Oncology July 2017 18(7):929-945
Subject
Language
ISSN
1470-2045